Top Page
Evaxion Biotech
(NASDAQ:EVAX)
Evaxion Biotech (EVAX) vs. SPDR S&P 500 ETF (SPY)
Evaxion Biotech Business Overview & Revenue Model
Evaxion Biotech Earnings Call Summary
Evaxion Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.65M | 3.34M | 73.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.65M | 3.34M | 73.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -5.96M | -9.79M | -21.40M | -22.57M | -24.21M | -16.46M |
| Net Income | -5.42M | -10.57M | -22.13M | -23.17M | -24.53M | -15.02M |
Balance Sheet | ||||||
| Total Assets | 29.74M | 12.48M | 12.89M | 22.02M | 40.16M | 11.96M |
| Cash, Cash Equivalents and Short-Term Investments | 10.57M | 5.05M | 4.18M | 13.18M | 32.17M | 5.83M |
| Total Debt | 0.00 | 10.10M | 10.87M | 10.26M | 3.69M | 20.00K |
| Total Liabilities | 13.14M | 14.14M | 17.62M | 13.72M | 7.73M | 4.93M |
| Stockholders Equity | 16.60M | -1.65M | -4.73M | 8.30M | 32.44M | 7.04M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -12.94M | -17.78M | -26.07M | -23.29M | -12.83M |
| Operating Cash Flow | 0.00 | -12.94M | -17.69M | -25.77M | -21.93M | -12.44M |
| Investing Cash Flow | 0.00 | -3.00K | -93.00K | -268.00K | -1.33M | -393.00K |
| Financing Cash Flow | 0.00 | 13.13M | 10.69M | 7.85M | 49.80M | 8.82M |
Evaxion Biotech Technical Analysis
Evaxion Biotech Risk Analysis
Evaxion Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $71.65M | ― | ― | ― | 234.73% | 81.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $34.33M | ― | ― | ― | 4455.07% | 77.31% | |
43 Neutral | $28.44M | ― | -3071.15% | ― | 36.89% | 43.58% | |
42 Neutral | $39.00M | -0.87 | ― | ― | -14.92% | 72.81% | |
41 Neutral | $35.78M | -4.85 | -83.34% | ― | -6.51% | 58.31% | |
41 Neutral | $26.58M | ― | ― | ― | ― | 49.57% |
Evaxion Biotech Corporate Events
On November 20, 2025, Evaxion A/S announced positive data from its cytomegalovirus (CMV) vaccine program, EVX-V1. The program, which leverages Evaxion’s AI-Immunology™ platform, has identified novel antigens that significantly reduce viral infection in preclinical models. This advancement is crucial as no CMV vaccine has been approved despite decades of research, highlighting the importance of these findings. The company continues to optimize and investigate these AI-derived antigens while exploring strategic partnerships to advance the vaccine into clinical phases.
On November 4, 2025, Evaxion Biotech announced a share capital increase following the exercise of certain investor warrants. This resulted in the issuance of 1,875,000 ordinary shares, raising the company’s share capital to nominal DKK 104,252,689. The capital increase, registered with the Danish Business Authority, reflects a cash consideration of USD 101,625. This move is part of Evaxion’s strategic efforts to strengthen its financial position and potentially enhance its market presence.
On November 12, 2025, Evaxion A/S announced its financial calendar for 2026, detailing key dates for business updates and financial results throughout the year. This announcement is significant for stakeholders as it outlines the company’s timeline for financial disclosures and strategic updates, which are crucial for investors and market analysts to track the company’s progress and financial health.
On November 7, 2025, Evaxion A/S announced new immune data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data, which builds on previous clinical efficacy results, highlights the vaccine’s ability to induce specific immune responses in patients with advanced melanoma when used in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®. This development further strengthens EVX-01’s data package and underscores its potential impact on cancer treatment, drawing significant interest from the medical community.
On November 6, 2025, Evaxion A/S announced significant business developments and financial results for the third quarter of 2025. Key highlights include the appointment of Dr. Helen Tayton-Martin as the new CEO, effective November 24, 2025, and the presentation of promising phase 2 trial data for their personalized cancer vaccine, EVX-01, at the ESMO Congress. The company also reported the out-licensing of their bacterial vaccine candidate, EVX-B3, to MSD, which has extended their cash runway to the second half of 2027. These developments underscore Evaxion’s strategic focus on leveraging its AI-Immunology™ platform for vaccine innovation and expanding its market presence through strategic partnerships.
On November 3, 2025, Evaxion A/S announced the expansion of its R&D pipeline with the introduction of EVX-04, a new AI-designed precision cancer vaccine candidate. EVX-04 targets non-conventional ERV tumor antigens and is designed as a therapeutic vaccine for acute myeloid leukemia. The vaccine, which induces strong T-cell responses, will be presented at the American Society of Hematology Annual Meeting in December, highlighting its potential to improve outcomes for patients who do not respond to conventional immunotherapies.
On October 31, 2025, Evaxion A/S announced it will provide a business update and report its third quarter 2025 financial results on November 6, 2025. The company will host a conference call and webcast to present the update and results, which will be open to the public. This announcement is part of Evaxion’s ongoing efforts to engage with stakeholders and provide transparency about its financial health and strategic direction.
Evaxion Biotech A/S announced amendments to its Articles of Association following the exercise of certain investor warrants, resulting in an increase in share capital. From October 15 to October 28, 2025, the company registered a total share capital increase of nominal DKK 4,735,475, raising the total share capital to DKK 103,783,939. This move, which involved the issuance of multiple ordinary shares over several days, reflects the company’s ongoing efforts to enhance its financial standing and operational capacity, potentially impacting its market position and shareholder value.
On October 30, 2025, Evaxion A/S announced it raised $7.2 million, extending its cash runway to the second half of 2027. This financial boost comes from the sale of shares and the exercise of warrants, strengthening Evaxion’s cash position and equity. The company has also reduced its outstanding warrants by 1.0 million, enhancing its financial stability. This development follows a $7.5 million payment from MSD for licensing a vaccine candidate in September 2025, further supporting Evaxion’s strategic focus on executing its R&D programs and operations.
On October 27, 2025, Evaxion A/S announced the appointment of Dr. Helen Tayton-Martin as the new Chief Executive Officer, effective November 24, 2025. Dr. Tayton-Martin, with over 30 years of experience in biotech, including leadership roles in cancer immunotherapy, is expected to lead Evaxion’s strategic execution. Her appointment is seen as a significant step for the company, which is well-positioned for future growth with its AI-Immunology platform and recent strategic partnerships. Additionally, Jens Bitsch-Norhave will join the Board of Directors as an advisor, bringing extensive experience in corporate strategy and global expansion.
On September 25, 2025, Evaxion Biotech A/S sold 1,018,000 American Depositary Shares (ADSs) in an at-the-market offering, generating approximately $4.3 million in proceeds. The company’s share capital increased significantly, with amendments to the Articles of Association reflecting these changes. Between October 3 and October 10, 2025, further share capital increases occurred due to the exercise of investor warrants, raising additional funds and expanding the company’s capital base. These financial activities are part of Evaxion’s strategic efforts to bolster its market position and operational capabilities.
On October 17, 2025, Evaxion Biotech announced impressive results from a phase 2 trial of its AI-designed personalized cancer vaccine, EVX-01, for advanced melanoma. The trial demonstrated a 75% Objective Response Rate, with 12 out of 16 patients showing clinical responses, and 92% of patients still responding after 24 months. The data, presented at the ESMO Congress, highlights the vaccine’s potential as a new treatment option and underscores the precision of Evaxion’s AI-Immunology platform in identifying neoantigens. The company plans further clinical development in partnership, marking a significant milestone in personalized immunotherapy.
On October 13, 2025, Evaxion A/S announced that it will present comprehensive data from its phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01, at the ESMO Congress 2025 in Berlin. The presentation will include two-year clinical efficacy, immunogenicity, and safety data, highlighting the vaccine’s potential in treating advanced melanoma. The trial, conducted in combination with Merck’s KEYTRUDA®, has shown promising results, including a 69% overall response rate and significant tumor-specific immune responses. This presentation underscores Evaxion’s innovative approach and strengthens its position in the personalized cancer vaccine sector.
On October 8, 2025, Evaxion A/S announced the expansion of its AI-Immunology™ platform with a new automated vaccine design module. This advancement automates previously manual processes, enhancing vaccine quality and significantly reducing design time and costs. The module is applicable for both new and existing vaccines, potentially leading to improved vaccine generations. Evaxion will present validation data on these improvements at the World Vaccine Congress Europe on October 15, 2025, highlighting its strategic focus on leading AI-based vaccine discovery and design.
On October 3, 2025, Evaxion A/S announced that it will present new biomarker data for its AI-designed personalized cancer vaccine, EVX-01, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data, stemming from an ongoing phase 2 trial, will contribute to the strong data package of EVX-01, which is being evaluated in combination with KEYTRUDA® for advanced melanoma. The presentation aims to highlight the vaccine’s efficacy and the predictive power of Evaxion’s AI-Immunology™ platform, potentially impacting the company’s industry positioning and offering significant insights for stakeholders.
On September 25, 2025, Evaxion A/S announced the out-licensing of its vaccine candidate EVX-B3 to MSD, marking a significant milestone in its strategic partnership. This agreement includes a $7.5 million cash payment to Evaxion, extending its cash runway into the first half of 2027, and potential milestone payments up to $592 million. MSD will assume full responsibility for the development of EVX-B3, while also retaining an option for a second vaccine candidate, EVX-B2, with a decision expected in the first half of 2026. This collaboration not only provides financial benefits but also validates Evaxion’s AI-Immunology™ platform, enhancing its industry positioning and potential for future partnerships.